The use of recovery animals in nonclinical safety assessment studies with monoclonal antibodies: further 3Rs opportunities remain
Helen Prior(National Centre for the Replacement Refinement and Reduction of Animals in Research), Lucinda Weir(GlaxoSmithKline (United Kingdom)), Michael W. Leach(Pfizer (United States)), Maggie Dempster(GlaxoSmithKline (United States)), Katrin Schütte(European Commission), Danuta J. Herzyk, Noël Dybdal, Adam Hey(AstraZeneca (United Kingdom)), Wendy Freebern(Bristol-Myers Squibb (Germany)), Leon van Aerts(Medicines Evaluation Board), Thomas Kissner(Sanofi (Germany)), Lolke de Haan(AstraZeneca (United Kingdom)), Annick Cauvin(UCB Pharma (Belgium)), Kaushik Datta(Bristol-Myers Squibb (Germany)), Hsiao-Tzu Chien(Radboud University Nijmegen), Kirsty Reid(European Federation of Pharmaceutical Industries and Associations), Donna Lee, Fiona Sewell(National Centre for the Replacement Refinement and Reduction of Animals in Research), Peter van Meer(Medicines Evaluation Board), David O. Clarke(Eli Lilly (United States)), Laura Andrews, Sven Kronenberg(Roche (Switzerland)), Peter Ulrich(University of Potsdam), Kevin Trouba(Janssen (United States))
Cited by 15
Related Papers
Cholera toxin: A paradigm for multi-functional engagement of cellular mechanisms (Review)
|Molecular Membrane Biology|2004|217
Biochemical and pharmacological characterization of different recombinant acid α-glucosidase preparations evaluated for the treatment of Pompe disease
|Molecular Genetics and Metabolism|2008|96
Re-evaluating the need for chronic toxicity studies with therapeutic monoclonal antibodies, using a weight of evidence approach
|Regulatory Toxicology and Pharmacology|2022|32
Survey results on the use of the tissue cross-reactivity immunohistochemistry assay
|Regulatory Toxicology and Pharmacology|2010|24